BioStock: WntResearch to focus on patient recruitment

The key take-away from the Q3 report of cancer therapy company WntResearch is that, so far, 93 patients have been randomised in the NeoFox study. Due to the pandemic, recruitment has been slower than expected, but the company is still aiming for an interim analysis covering 120 patients in December 2022.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/12/wntresarch-to-focus-on-patient-recruitment/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se